Fungal Infection News and Research

RSS

Unusual compounds in pitcher plant could prove effective against human fungal infections

The moment insects like flies, ants and beetles fall into a pitcher, the plant's enzymes are activated and begin dissolving their new meal, obtaining nutrients such as carbon and nitrogen which are difficult to extract from certain soils.

19 Feb 2010

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

Anacor Pharmaceuticals announced today that Merck has returned full worldwide development and commercialization rights for AN2690 to Anacor. AN2690 is a topical anti-fungal therapy being developed for onychomycosis, a fungal infection of the nail and nail bed. It is estimated that onychomycosis affects approximately 35 million people in the United States.

12 Feb 2010

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections).

1 Feb 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010

Scientists determine structure of enzyme essential to the survival of protozoan parasites

After many years of study, a team of researchers is releasing data today that it hopes will lead to new drug therapies that will kill the family of parasites that causes a deadly trio of insect-borne diseases and has afflicted inhabitants of underdeveloped and developing nations for centuries.

18 Jan 2010

GSK and NanoBio sign license agreement for nanoemulsion technology

GlaxoSmithKline and Ann Arbor-based NanoBio Corporation announced today that they have signed an exclusive over-the-counter licensing agreement for NanoBio's unique nanoemulsion treatment for cold sores in the United States and Canada.

17 Dec 2009

Proteins from catfish venom glands could accelerate wound healing in humans

Lest anyone have concerns about attacks of killer catfish, rest assured that, at least in North America, these finned fatales use their venom mainly to defend themselves against predatory fish, though they can inflict a painful sting that many fishermen have suffered. In other parts of the world, some catfish do have extremely toxic venoms that can be deadly to humans.

11 Dec 2009

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.

9 Dec 2009

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pacific Beach BioSciences, Inc. today reported that it has granted non-exclusive rights to a large pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

9 Dec 2009

Pilot clinical study results of laser treatment for toenail fungus presented

PinPointe USA, Inc., a privately held emerging medical technology company which introduced the breakthrough PinPointe FootLaser treatment for toenail fungus in Europe, today announced that Dr. Brian McDowell presented the results of his pilot clinical study “Laser Treatment for Toenail Fungus” (Harris, McDowell and Strisower, Proc. SPIE 7161A, 2009) at the Society of Chiropodists and Podiatrists Annual Conference 2009 at Harrogate International Centre on November 19.

25 Nov 2009

WPI researchers develop new model system to study fungal infections

A team of researchers at the Worcester Polytechnic Institute (WPI) Life Sciences and Bioengineering Center at Gateway Park has developed a new model system to study fungal infections. The system can be a powerful tool for screening potential drug targets for conditions like thrush, athlete's foot and vaginal yeast infections, which affect millions of people each year but are difficult to treat with existing medications. Using the new model, the researchers also identified a gene that may be a promising target for a new anti-fungal drug.

20 Nov 2009

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.

7 Nov 2009

Researchers discover a fungal protein that causes disease in plants and animals

Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech and Montana State University have discovered a fungal protein that plays a key role in causing disease in plants and animals and which also shields the pathogen from oxidative stress.

7 Nov 2009

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

7 Nov 2009

Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Diabetes may damage nerves in the skin leading to dry skin, say experts

As American Diabetes Month approaches, leading experts like Dr. Jacqueline Sutera, DPM, stress the importance of foot care, especially for those with diabetes. People with diabetes are at a greater risk of developing dry skin due to nerve damage.

30 Oct 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments.

29 Oct 2009

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures.

28 Oct 2009

Fungal Infection News and Research

Unusual compounds in pitcher plant could prove effective against human fungal infections

Merck returns worldwide development and commercialization rights for AN2690 to Anacor Pharmaceuticals

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

New biomarker may predict treatment outcomes in RA patients

Scientists determine structure of enzyme essential to the survival of protozoan parasites

GSK and NanoBio sign license agreement for nanoemulsion technology

Proteins from catfish venom glands could accelerate wound healing in humans

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pilot clinical study results of laser treatment for toenail fungus presented

WPI researchers develop new model system to study fungal infections

Transatlantic task force to address antibiotic resistance established, experts welcome initiative

Researchers discover a fungal protein that causes disease in plants and animals

Experts applaud the EU Presidency for establishing a transatlantic task force to address antibiotic resistance

Phase III study results on miconazole Lauriad presented by BioAlliance Pharma

Safeguard Scientifics reports financial results for the third quarter of 2009

Diabetes may damage nerves in the skin leading to dry skin, say experts

Genetic mutations may put individuals at increased risk for fungal infections

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News